Alaunos Therapeutics, Inc. (TCRT)

Market Cap	5.54M -23.1%
Revenue (ttm)	3,000 -50.0%
Net Income	-4.12M
EPS	-1.77
Shares Out	2.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,672,624
Open	2.030
Previous Close	2.070
Day's Range	1.800 - 2.390
52-Week Range	0.719 - 4.500
Beta	-0.87
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About TCRT

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1
• Stock Exchange: Nasdaq
• Ticker Symbol: TCRT
• Website: https://www.alaunos.com

Financial Performance

In 2025, Alaunos Therapeutics's revenue was $5,000, a decrease of -50.00% compared to the previous year's $10,000. Losses were -$4.28 million, -8.48% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error